Research Tracker›Biomarker Atlas›Long COVID›Platelet hyperactivation

Platelet hyperactivation in Long COVID

Platelet hyperactivation, also described as P-selectin, GP IIb/IIIa, is a coagulation marker reported as elevated in Long COVID (PASC, Post-Acute Sequelae of COVID-19) when patients are compared with healthy controls. Symptom domains tied to this marker in the source include thromboinflammation. The finding is drawn from Pretorius et al. 2023; it describes group-level differences, not a threshold that classifies an individual.

↑ ElevatedCoagulation

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryCoagulation
Also described asP-selectin, GP IIb/IIIa
Compared againstHC (healthy controls)
Associated symptomsThromboinflammation
Test typeBlood test (serum / plasma / whole blood)
SourcePretorius et al. 2023 — doi:10.1186/s12933-023-01931-4
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term sP selectin (2 registered trials use a matching outcome measure).

Clinical trials using Platelet hyperactivation as an outcome

Related Coagulation markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Platelet hyperactivation high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher Platelet hyperactivation in Long COVID than in healthy controls. Source: Pretorius et al. 2023.

What symptoms is Platelet hyperactivation associated with in Long COVID?

The cited literature associates this marker with Thromboinflammation. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Platelet hyperactivation?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Platelet hyperactivation result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Platelet hyperactivation findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Platelet hyperactivation in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/platelet-hyperactivation.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.